中国生物制药宣布,其创新药物IM-101注射液已获得中国国家药品监督管理局的临床试验批准,将针对慢性乙型肝炎适应症展开临床研究。这一进展标志着公司在肝病治疗领域的研发管线取得重要突破,有望为慢性乙肝患者提供新的潜在治疗选择。公司表示,将严格按照相关法规要求,尽快推进该药物的临床开发工作。
中国生物制药宣布,其创新药物IM-101注射液已获得中国国家药品监督管理局的临床试验批准,将针对慢性乙型肝炎适应症展开临床研究。这一进展标志着公司在肝病治疗领域的研发管线取得重要突破,有望为慢性乙肝患者提供新的潜在治疗选择。公司表示,将严格按照相关法规要求,尽快推进该药物的临床开发工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.